The subject of this publication is the conclusion of agreements in accordance with Section 130 a (8) SGB V on finished medicinal products with various active substances or combinations of active substances within the framework of a so-called “open house model”.

The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out.

The earliest contract commencement date is 1.7.2021. Based on this, the contract period is a maximum of 12 or 24 months. The contract ends on 30 June 2022 and 30 June 2023, irrespective of the commencement of the contract.

If AOK Hessen should carry out an invitation to tender for exclusive contracts in the form of an open procedure during the contract period, the contracts concluded as part of this publication will be terminated in accordance with the contractual regulations.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact the I.1. Request the participation documents and the contract from the contact address given. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. This publication is not exclusive and is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to procurement law regulations, unless they are mandatory for legal reasons.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact the I.1. Request the participation documents and the contract from the contact address given. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. This publication is not exclusive and is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to procurement law regulations, unless they are mandatory for legal reasons.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact the I.1. Request the participation documents and the contract from the contact address given. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. This publication is not exclusive and is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to procurement law regulations, unless they are mandatory for legal reasons.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact the I.1. Request the participation documents and the contract from the contact address given. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. This publication is not exclusive and is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to procurement law regulations, unless they are mandatory for legal reasons.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact the I.1. Request the participation documents and the contract from the contact address given. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. This publication is not exclusive and is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to procurement law regulations, unless they are mandatory for legal reasons.

All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement pursuant to Section 130a (8) SGB V on the active substances referred to in Section B, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies may request the participation documents and the contract from the contact address referred to in I.1. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the eligibility requirements. Exclusivity is not given. This publication does not constitute the award of a public contract within the meaning of Directive 2014/24/EU or public procurement law. In order to ensure the widest possible level of transparency for the contracts envisaged, publication is made in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the “open procedure” method designation, are solely due to the use of this notice form and the publication platform. There is no other importance, in particular subjection to public procurement rules, insofar as they are not compulsory for legal reasons.

All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement pursuant to Section 130a (8) SGB V on the active substances referred to in Section B, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies may request the participation documents and the contract from the contact address referred to in I.1. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the eligibility requirements. Exclusivity is not given. This publication does not constitute the award of a public contract within the meaning of Directive 2014/24/EU or public procurement law. In order to ensure the widest possible level of transparency for the contracts envisaged, publication is made in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual specifications, such as the

The term 'open procedure' is solely due to the use of this notice document and the publication platform. There is no other importance, in particular subjection to public procurement rules, insofar as they are not compulsory for legal reasons.

All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement pursuant to Section 130a (8) SGB V on the active substances referred to in Section B, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies may request the participation documents and the contract from the contact address referred to in I.1. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the eligibility requirements. Exclusivity is not given. This publication does not constitute the award of a public contract within the meaning of Directive 2014/24/EU or public procurement law. In order to ensure the widest possible level of transparency for the contracts envisaged, publication is made in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual specifications, such as the

The term 'open procedure' is solely due to the use of this notice document and the publication platform. There is no other importance, in particular subjection to public procurement rules, insofar as they are not compulsory for legal reasons.

All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement pursuant to Section 130a (8) SGB V on the active substances referred to in Section B, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies may request the participation documents and the contract from the contact address referred to in I.1. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the eligibility requirements. Exclusivity is not given. This publication does not constitute the award of a public contract within the meaning of Directive 2014/24/EU or public procurement law. In order to ensure the widest possible level of transparency for the contracts envisaged, publication is made in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual specifications, such as the

The term 'open procedure' is solely due to the use of this notice document and the publication platform. There is no other importance, in particular subjection to public procurement rules, insofar as they are not compulsory for legal reasons.

All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement pursuant to Section 130a (8) SGB V on the active substances referred to in Section B, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies may request the participation documents and the contract from the contact address referred to in I.1. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the eligibility requirements. Exclusivity is not given. This publication does not constitute the award of a public contract within the meaning of Directive 2014/24/EU or public procurement law. In order to ensure the widest possible level of transparency for the contracts envisaged, publication is made in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual specifications, such as the

The term 'open procedure' is solely due to the use of this notice document and the publication platform. There is no other importance, in particular subjection to public procurement rules, insofar as they are not compulsory for legal reasons.

All suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to enter into or join a discount agreement pursuant to Section 130a (8) SGB V on the active substances referred to in Section B, subject to uniform contract conditions and a uniform access procedure. Interested pharmaceutical companies may request the participation documents and the contract from the contact address referred to in I.1. The contract shall be subject to the conclusion of a contract that the interested pharmaceutical company shall complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the eligibility requirements. Exclusivity is not given. This publication does not constitute the award of a public contract within the meaning of Directive 2014/24/EU or public procurement law. In order to ensure the widest possible level of transparency for the contracts envisaged, publication is made in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual specifications, such as the

The term 'open procedure' is solely due to the use of this notice document and the publication platform. There is no other importance, in particular subjection to public procurement rules, insofar as they are not compulsory for legal reasons.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact the I.1. Request the participation documents and the contract from the contact address given. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. This publication is not exclusive and is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to procurement law regulations, unless they are mandatory for legal reasons.